ToxInvent is developing and out-licensing new molecules with the applications for the personal anticancer thepary.
The scientific team of ToxInvent has more than 20 years experience in chemistry of monomethyl auristatins and anthracyclines. We have designed and synthesized a set of novel payloads for Antibody Drug Conjugates.
At the moment we are working on our first ADC prototype.
ToxInvent has a pending patent on those proprietary products and their applications.